Literature DB >> 15959658

Global consensus on ADHD/HKD.

Helmut Remschmidt1.   

Abstract

A Global ADHD Working Group of experienced clinicians and researchers was gathered to review the latest evidence, discuss current best practice in the treatment of attention-deficit/hyperactivity disorder (ADHD), and make a statement based on consensus. The statement aims to re-affirm ADHD as a valid disorder that exists across different cultures, has a significant global impact, and should be diagnosed and effectively treated wherever it occurs. ADHD is one of the most common neurobehavioural disorders of childhood and impacts on many aspects of development, including social, emotional and cognitive functioning, in the home and school environment. Although these findings are from developed countries, the impact in developing countries is likely to be similar. There is strong supportive evidence for the validity of ADHD as a syndrome with neurobiological aspects, and complex genetic factors are primarily implicated in the aetiology. Accurate diagnosis and measurement of impairment is important to enable appropriate and successful management of symptoms. ADHD is a persistent condition that needs to be treated and monitored over time. The evidence supporting medication-based interventions (such as methylphenidate) is strong and consensus treatment algorithms to guide the multimodal treatment of ADHD, alone and in combination with common comorbidities, are suggested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959658     DOI: 10.1007/s00787-005-0439-x

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  9 in total

Review 1.  Genetics of childhood disorders: XX. ADHD, Part 4: is ADHD genetically heterogeneous?

Authors:  S V Faraone
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-11       Impact factor: 8.829

Review 2.  Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Authors:  Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-02       Impact factor: 8.829

Review 3.  Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics.

Authors: 
Journal:  Pediatrics       Date:  2000-05       Impact factor: 7.124

4.  Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.

Authors:  F X Castellanos; J N Giedd; J Elia; W L Marsh; G F Ritchie; S D Hamburger; J L Rapoport
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-05       Impact factor: 8.829

5.  International Consensus Statement on ADHD.

Authors:  Russell A Barkley
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-12       Impact factor: 8.829

6.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

Review 7.  The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: Tactics. Attention-Deficit/Hyperactivity Disorder.

Authors:  S R Pliszka; L L Greenhill; M L Crismon; A Sedillo; C Carlson; C K Conners; J T McCracken; J M Swanson; C W Hughes; M E Llana; M Lopez; M G Toprac
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-07       Impact factor: 8.829

8.  Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

Review 9.  International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions.

Authors:  Stan Kutcher; Michael Aman; Sarah J Brooks; Jan Buitelaar; Emma van Daalen; Jörg Fegert; Robert L Findling; Sandra Fisman; Laurence L Greenhill; Michael Huss; Vivek Kusumakar; Daniel Pine; Eric Taylor; Sam Tyano
Journal:  Eur Neuropsychopharmacol       Date:  2004-01       Impact factor: 4.600

  9 in total
  23 in total

1.  Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Authors:  Wen-Jiun Chou; Shin-Jaw Chen; Ying-Sheue Chen; Hsin-Yi Liang; Chih-Chien Lin; Ching-Shu Tang; Yu-Shu Huang; Chin-Bin Yeh; Miao-Chun Chou; Dai-Yueh Lin; Po-Hsun Hou; Yu-Yu Wu; Hung-Jen Liu; Ya-Fen Huang; Kai-Ling Hwang; Chin-Hong Chan; Chia-Ho Pan; Hsueh-Ling Chang; Chi-Fen Huang; Ju-Wei Hsu
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

Review 2.  A Systematic Review and Evaluation of Clinical Practice Guidelines for Children and Youth with Disruptive Behavior: Rigor of Development and Recommendations for Use.

Authors:  Brendan F Andrade; Darren Courtney; Stephanie Duda; Madison Aitken; Stephanie G Craig; Peter Szatmari; Joanna Henderson; Kathryn Bennett
Journal:  Clin Child Fam Psychol Rev       Date:  2019-12

Review 3.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 4.  Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Authors:  Jochen Antel; Özgür Albayrak; Gerd Heusch; Tobias Banaschewski; Johannes Hebebrand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-23       Impact factor: 5.270

Review 5.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 6.  [Multimodal treatment of attention-deficit hyperactivity disorder in children].

Authors:  T Jans; S Kreiker; A Warnke
Journal:  Nervenarzt       Date:  2008-07       Impact factor: 1.214

7.  What single reports from children and parents aggregate to attention deficit-hyperactivity disorder and oppositional defiant disorder diagnoses in epidemiological studies.

Authors:  Rosario Granero; Lourdes Ezpeleta; José María Domenech; Nuria de la Osa
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-04-21       Impact factor: 4.785

8.  Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.

Authors:  Pär Svanborg; Gunilla Thernlund; Per A Gustafsson; Bruno Hägglöf; Lynne Poole; Björn Kadesjö
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-01-20       Impact factor: 4.785

9.  Effects of psycho-educational training and stimulant medication on visual perceptual skills in children with attention deficit hyperactivity disorder.

Authors:  Antigone S Papavasiliou; Irene Nikaina; Ioanna Rizou; Stratos Alexandrou
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.

Authors:  Pär Svanborg; Gunilla Thernlund; Per A Gustafsson; Bruno Hägglöf; Alexander Schacht; Björn Kadesjö
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-05-23       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.